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ABSTRACT
Objectives: To describe the prevalence of brain MRI
incidental findings (IF) in a cohort of cognitively
normal first-degree descendants of patients with
Alzheimer’s disease (AD).
Design: Cross-sectional observational study.
Setting: All scans were obtained with a 3.0 T scanner.
Scans were evaluated by a single neuroradiologist and
IF recorded and categorised. The presence of white
matter hyperintensities (WMH) was determined with
the Fazekas scale and reported as relevant if ≥2.
Participants: 575 participants (45–75 years)
underwent high-resolution structural brain MRI.
Participants were cognitively normal and scored over
the respective cut-off values in all the following
neuropsychological tests: Mini-Mental State
Examination (≥26), Memory Impairment Screen (≥6),
Time Orientation Subtest of the Barcelona Test II
(≥68), verbal semantic fluency (naming animals ≥12).
Clinical Dementia Rating (CDR) had to be 0.
Results: 155 participants (27.0%) presented with at
least one IF. Relevant WMH were present in 7.8% of
the participants, and vascular abnormalities, cyst and
brain volume loss in 10.7%, 3.1% and 6.9% of the
study volunteers, respectively. Neoplastic brain findings
were found in 2.4% of participants and within these,
meningiomas were the most common (1.7%) and
more frequently found in women. A positive correlation
between increasing age and the presence of IF was
found. Additionally, brain atrophy greater than that
expected by age was significantly more prevalent in
participants without a parental history of AD.
Conclusions: Brain MRIs of healthy middle-aged
participants show a relatively high prevalence of IF
even when study participants have been screened for
subtle cognitive alterations. Most of our participants
are first-degree descendants of patients with AD, and
therefore these results are of special relevance for
novel imaging studies in the context of AD prevention
in cognitively healthy middle-aged participants.
Trial registration number: NCT02198586.
INTRODUCTION
MRI provides excellent spatial resolution and
tissue characterisation without making use of
ionising radiation. These advantages have
spurred its use to image the brains of healthy
individuals in clinical and research settings.1 2
In these scans, it is not unusual to detect inci-
dental findings (IF): unexpected abnormalities
of potential clinical significance and unrelated
to the purpose of the study. Estimating the
chance of discovering IF is important to help
clinicians and researchers to adequately
Strengths and limitations of this study
▪ Estimating the chance of discovering incidental
findings (IF) helps clinicians and researchers to
adequately inform and manage these situations.
▪ One hundred and fifty-five participants (27.0%),
most of them cognitively normal first-degree
descendants of patients with Alzheimer’s disease
(AD), presented with at least one IF.
▪ All images were reviewed by the same radiolo-
gist, thus maximising the homogeneity of the
readings and reports.
▪ Our results are relevant for studies aimed at pre-
venting AD in cognitively healthy middle-aged
participants with increased risk of developing the
disease.
▪ The generalisability of the results to the general
population may be limited.
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inform individuals and grant adequate access to standard
medical care in order to manage these situations.3
Therefore, in experimental protocols of human brain
imaging research, it is important to anticipate the detec-
tion of IF and establish proper pathways for their manage-
ment according to clinical and ethical considerations.4 5
The prevalence of IF reported in the literature shows
a great variability as a function of several factors: the spe-
cific cohort characteristics, the image sequence in the
MRI protocol (including whether contrast is used or
not), the experience and number of image readers and
the use of predefined analysis protocols and the postpro-
cessing methodology of the images.6 7 In a recent
meta-analysis that included 19 559 participants aged
between 11 and 63 years, an IF prevalence of 2.7% was
found.3 In particular, markers of cerebrovascular disease
were excluded from this analysis. The authors concluded
that IF prevalence increased with age and with higher
resolution of the scans. In agreement, other studies in
older populations have found significantly higher occur-
rences of IF. In observational studies, 32% (from a total
of 700 participants, mean age 72.5 years),7 9.5% (from a
total of 5800 participants with a mean age of
64.9 years)8 and 77.9% (from a total of 503 participants
with a mean age of 75.3 years)9 of asymptomatic partici-
pants presented with IF. Therefore, IF are commonly
revealed in neuroimaging research, but their occurrence
greatly differs between study populations.
In addition to these factors, the discrepancy in the
reported IF prevalence can also be accounted for by the
definition of what constitutes a ‘finding’. For example,
white matter hyperintensities (WMH) are often reported
as ‘normal’ findings in elderly individuals, since more
than half of the healthy elderly population (>65 years
old) has some degree of white matter lesions10 and this
proportion is even higher in individuals with vascular
risk factors such as hypertension and diabetes.11–13
In this manuscript, we describe the prevalence of
brain MRI IF in a cohort of 575 cognitively normal parti-
cipants of the ALFA (for Alzheimer and Families) study
(Molinuevo et al. The ALFA project: a research platform
to identify early pathophysiological features of
Alzheimer’s disease. Submitted). Current research sup-
ports that Alzheimer’s disease (AD) pathology develops
for several years before the onset of clinical symptoms.14
The main goal of the ALFA study is to characterise the
preclinical stage of AD and the most salient characteris-
tic of this cohort is the elevated percentage of first-
degree descendants of patients with AD. We compared
the prevalence of IF in first-degree relatives of patients
with AD versus non-relatives. Since familiar history is a
common enrichment strategy for AD prevention trials
(eg, PREVENT-Alzheimer programme;15 the Adult chil-
dren Study16 and the Wisconsin Registry for Alzheimer’s
Prevention Program17), this might be of interest in the
scope of novel studies aimed at preventing AD in cogni-
tively healthy participants with increased risk of develop-
ing the disease (Molinuevo et al, Submitted).1 18
METHODS
Participants
The ALFA parent cohort, established by the
Barcelonaβeta Brain Research Center (BBRC), is com-
posed of 2743 cognitively healthy participants, mostly
adult children of patients with AD, aged between 45 and
75 years, and was formed as a research platform from
which to establish studies for the detection of factors
indicative of AD in asymptomatic individuals (for a full
description of the ALFA population, please refer to the
Clinicaltrials.gov Identifier: NCT01835717 and ref. 19).
ALFA participants were cognitively normal and scored
over the respective cut-off values in all the following
neuropsychological tests: Mini-Mental State Examination
(≥26),20 Memory Impairment Screen (≥6),21 Time
Orientation Subtest of the Barcelona Test II (≥68),22
verbal semantic fluency (naming animals ≥12).23
Clinical Dementia Rating (CDR) had to be 0.24 All
ALFA cohort participants were asked about their paren-
tal history of AD at baseline and categorised as family
history positive (FH+) if they had at least one of their
parents who had been diagnosed with AD before the
age of 75. FH+ and FH− matched by sex and age groups
were invited to participate in the present study
(NCT02198586) which resulted in the inclusion of 608
individuals of the ALFA parent cohort that had no con-
traindications to brain MRI. Recruitment was initiated in
April 2014 and finished in June 2015.
Ethical considerations
The MRI study protocol registered at Clinicaltrials.gov
(Identifier: NCT02198586). It has been conducted in
accordance with the directives of the Spanish Law 14/
2007, of 3rd of July, on Biomedical Research (Ley 14/
2007 de Investigación Biomédica). All participants
accepted the study procedures by signing an informed
consent form.
Brain MRI acquisition characteristics
Scans were obtained with a 3.0 T scanner (GE Discovery
MR750 W 3T). The MRI protocol was identical for
all participants and included high-resolution three-
dimensional structural images weighted in T1 with an
isotropic voxel size of 1 mm3. The acquisition para-
meters were TR/TE/TI=8.0/3.7/450 ms, NSA=1, flip
angle=8° and a matrix size of 256×256×160. In addition,
three T2-weighted sequences (256×256, 1×1×3 mm
matrix) were acquired: fluid attenuation inversion recov-
ery (FLAIR: TR/TE/TI=11 000/90/2600 ms, flip
angle=160°), fast spin echo (TR/TE=5000/85 ms, flip
angle=110°) and gradient-recalled echo (GRE: TR/
TE=1300/23 ms, flip angle=15°).
Radiological reporting
Scans were evaluated by the same trained neuroradiolo-
gist within the following week from MRI acquisition. All
participants received the neuroradiological report of the
MRI. An independent clinical consultant reviewed those
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that contained IF and clinically relevant IF (eg, tumours,
vascular abnormalities, WMH with comorbidities, cysts,
chiari malformations, syringomyelia, ventriculomegaly
suspicious of normal pressure hydrocephalus and ence-
phalomalacia) were personally informed and partici-
pants referred for follow-up to the appropriate specialist
(n=90/155). All individuals were offered a telephonic
helpline should they present with additional questions
or need further clarifications on the findings.
WMH were evaluated using the Fazekas scale,25 a well-
validated and established qualitative visual rating
method, which separately categorises the severity of
deep and periventricular lesions, on a scale from 0 to 3
(0: none or a single punctate WHM lesion, (1) multiple
punctate lesions, (2) beginning confluency of lesions
(bridging) and (3) large confluent lesions). WMH of
Fazekas score ≥2 were reported as IF because, despite
appearing in some normally functioning participants,
these values are considered as relevant.9 26 27 Brain
volume loss was considered as IF by the radiologist when
it was greater than that expected by age.
Statistical analyses
IF were categorised as WMH, vascular abnormalities
(including lacunar infarcts, microhaemorrhages, aneur-
ysms, cavernous malformations and malformations of
venous development), cysts, neoplasias and others,
including brain volume loss, and their prevalence calcu-
lated. The CIs were computed by Bayesian calculation.
The effect of ageing in the most prevalent IF was assessed
by means of a Pearson product-moment correlation coef-
ficient (r). We also stratified participants into three differ-
ent groups according to their age (between 45 and 54,
between 55 and 64 and between 65 and 75). IF’s preva-
lence per sex and age group was also quantified. The χ2
test was used to assess for statistically significant differ-
ences in each most prevalent IF category between sexes
and in brain atrophy and WMH between participants
with or without a family history of AD. SPSS V.15.0 for
Windows was used for all the statistical analyses.
Differences were considered to be significant at p<0.05.
RESULTS
Six hundred and eight ALFA parent cohort participants
were invited to take part in the present brain MRI study.
Of these, 595 volunteers agreed to undergo MRI and 575
provided valid MRIs. Reasons that prevented MRI acquisi-
tion were claustrophobia (n=16), physical size or shape
that precluded from lying in the scanner (n=3), and an
imaging artefact caused by irremovable MRI-compatible
metallic earrings (n=1). The main sociodemographic
characteristics of the study participants and the results of
the neuropsychological screening tests are shown in
table 1. Out of the 575 individuals included in the study,
227 (39.5%) were men and 348 (60.5%) women, with a
mean age of 58.2 and 57.5 years, respectively.
Prevalence of IF
One hundred and fifty-five (27.0% (95% CI 23.5% to
30.7%)) participants presented with at least one IF: 64
were men (mean age 57.7 years) and 91 women (mean
age 57.8 years). Table 2 shows the prevalence of each IF.
With regard to WMH, 43 (7.4% (95% CI 5.6% to
9.9%)) individuals presented with a Fazekas 2 and 2
(0.3% (95% CI 0.1% to 1.2%)) with a Fazekas 3. Vascular
abnormalities were present in 10.7% (95% CI 8.6% to
13.6%) of the study participants, the most prevalent being
malformations of venous development (3.4% (95% CI
2.2% to 5.3%)) and lacunar infarcts (2.9% (95% CI 1.8%
to 4.7%)) followed by single cavernous malformations
(2.4% (95% CI 1.4% to 4.0%)) and microhaemorrhages
(1.5% (95% CI 0.8% to 2.9%)). Cysts, including arach-
noid and neuroepithelial ones, were found in 3.1% (95%
CI 1.9% to 4.8%) of the cases. The prevalence of neopla-
sias was of 2.4% (95% CI 1.5% to 4.0%), whereas 10 parti-
cipants (1.7% (95% CI 0.9% to 3.2%)) presented with a
meningioma. Concerning other abnormalities, 7.0%
(95% CI 5.1% to 9.3%) of the participants showed a brain
volume loss greater than that expected by age and 1.0%
(95% CI 0.5% to 2.2%) of them had a Chiari type I mal-
formation. Finally, nine participants presented with extra-
cerebral findings. Representative images of specific IF can
be found in figure 1.





(SD) MMSE MIS TO SF
45–54 years 49.8
60.53
14.2 29.2 7.9 70 23.4
(n=211) (2.3) (3.3) (0.9) (0.4) (0.0) (4.9)
55–64 years 59.6
60.8
13.6 29.0 7.8 70 22.4
(n=245) (2.8) (3.6) (1.1) (0.5) (0.0) (5.3)
65–75 years 68.3
56.7
12.9 28.8 7.6 70 21.2
(n=119) (2.9) (3.6) (1.2) (0.6) (0.0) (5.0)
Total 58.6
57.8
13.6 29 7.7 70 22.5
(N=575) (7.3) (3.5) (1.1) (0.5) (0.0) (5.2)
MIS, Memory Impairment Screen; MMSE, Mini-Mental State Examination; SF, verbal Semantic Fluency (naming animals); TO, Time
Orientation Subtest of the Barcelona Test II.
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Age-specific distribution of IF
As a whole, a positive correlation between the preva-
lence of IF and increasing age was found (r=0.254,
p<0.001). IF were more frequent in the 65–75 years old
group (n=54, 45.4% (95% CI 36.7% to 54.3%)) than in
the 55–64 years old (n=68, 27.8% (95% CI 22.5% to
33.7%)) and the 45–54 years old (n=33, 15.6% (95% CI
11.4% to 21.2%)) ones. Table 3 shows the age-specific
distribution of the most frequent IF.
With regard to specific categories, a positive correlation
was found between the incidence of relevant WMH
(r=0.165, p<0.001), vascular abnormalities (r=0.125,
p=0.003) and brain volume loss (r=0.358, p<0.001) with
increasing age. Concerning vascular abnormalities, a
statistically significant higher prevalence of both lacunar
infarcts (r=0.116, p≤0.005) and microhaemorrhages
(r=0.136, p=0.001) with increasing age was also found.
With respect to brain volume loss, cortical atrophy
Table 2 Prevalence of incidental findings
Finding n (%) 95% CI
White matter hyperintensities* 45 (7.83) (5.9 to 10.3)
Vascular abnormalities
Lacunar infarcts 17 (2.96) (1.8 to 4.7)
Microhaemorrhages (n=9)
Single (cortical/deep) 2 (0.35)/2 (0.35) (0.10 to 1.24)/(0.10 to 1.24)
Various (cortical/deep) 4 (0.70)/1 (0.17) (0.28 to 1.77)/(0.04 to 0.96)
Structural vascular abnormalities (n=36)
Aneurysm 1 (0.17) (0.04 to 0.96)
Cavernous malformation (single/various) 14 (2.43)/1 (0.17) (1.466 to 4.04)/(0.04 to 0.96)
Malformation of venous development 20 (3.48) (2.27 to 5.31)
Cysts
Arachnoid (supratentorial/infratentorial) 3 (0.52)/5 (0.87) (0.19 to 1.51)/(0.38 to 2.01)
Pineal† 2 (0.35) (0.10 to 1.24)
Neuroepithelial 1 (0.17) (0.04 to 0.96)
Choroidal fissure cyst 2 (0.35) (0.10 to 1.24)
Posterior fossa cyst‡ 4 (0.70) (0.28 to 1.77)
Right hippocampus cyst 1 (0.17) (0.04 to 0.96)
Neoplasias
Meningioma 10 (1.74) (0.95 to 3.16)
Pituitary mass 2 (0.35) (0.10 to 1.24)
Small intraventricular mass§ 1 (0.17) (0.04 to 0.96)
Cerebellar hemispheric mass 1 (0.17) (0.04 to 1.96)
Other abnormalities
Brain volume loss¶ (n=40)
Frontal 8 (1.39) (0.71 to 2.71)
Temporal 8 (1.39) (0.71 to 2.71)
Parietal 7 (1.22) (0.60 to 2.48)
Cerebellum and brain stem 4 (0.69) (0.28 to 1.77)
Diffuse loss of brain volume 13 (2.26) (1.33 to 3.82)
Chiari malformation type I 6 (1.04) (0.49 to 2.25)
Syringomyelia 1 (0.17) (0.04 to 0.96)
Ventriculomegaly suspicious of NPH** 2 (0.35) (0.10 to 1.24)
Non-specific focus of altered signal†† 4 (0.52) (0.28 to 1.77)
Extracerebral findings (n=9)
Left frontal hyperostosis 1 (0.17) (0.04 to 0.96)
Signal alterations of clivus 1 (0.17) (0.04 to 0.96)
Other otorhinolaryngological processes‡‡ 6 (1.04) (0.49 to 2.25)
Right eye diameter increased 1 (0.17) (0.04 to 0.96)
Encephalomalacia after traumatic brain injury 1 (0.17) (0.04 to 0.96)
*Fazekas scale score ≥2.
†>1 cm in diameter.
‡Arachnoid cyst versus mega cisterna magna.
§Possible subependymoma.
¶Enlargement of the subarachnoid spaces and sulcus (bigger than that expected by age).
**Normal pressure hydrocephalus.
††Excluding white matter hyperintensities related to small vessel disease.
‡‡Excluding mild inflammatory disease (mucosal thickening or small retention cysts).
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showed a positive correlation (r=0.240, p<0.001), whereas
cerebellar and brain stem atrophies did not.
Sex-specific distribution of IF
We found no statistically significant differences between
genders in the general prevalence of IF (p=0.589).
Unexpected findings were found in 28.2% of the men
and 26.1% of the women. When the most prevalent cat-
egories of IF were analysed, statistically significant differ-
ences between sexes were found in brain volume loss
(p=0.039) that was more frequent in men (9.7% (95%
CI 6.5% to 14.2%)) than women (5.2% (95% CI 3.3%
to 8.0%)) and quasi-significant differences in neoplasias
(p=0.051) that were more prevalent in women (4.3%
(95% CI 2.6% to 6.9%)) than in men (1.3% (95% CI
0.5% to 3.8%)). Within neoplasias, meningiomas were
more frequent in women (n=9 women, n=1 man). None
of the other IF categories showed statistically significant
differences between genders.
Family history of AD and prevalence of IF
As a whole, we found no statistically significant differ-
ences in the prevalence of IF between participants who
had a family history of AD and those who did not
(p=0.149). IF were found in the 24.9% (95% CI 20.8%
to 29.6%) of participants with a positive family history of
AD and the 30.5% (95% CI 24.6% to 37.0%) of indivi-
duals with no family history of AD. The prevalence of
WMH (p=0.408) was not significantly different between
volunteers with or without a family history.
Unexpectedly, brain volume loss showed significant dif-
ferences (p=0.005) between groups being more preva-
lent in the FH− group (table 4).
DISCUSSION
In this study, we aimed at describing the prevalence of
IF from brain MRI in healthy participants aged between
45 and 75 of a population-based study, most of them
first-degree descendants of patients with AD. The IF
found were classified on the basis of their MRI
characteristics alone and were not confirmed by further
studies. IF were found in 27.0% of the participants,
which is similar to studies involving older participants7
and higher than the prevalence typically reported in
most previous studies with comparable populations.8
Figure 1 Incidental findings on brain MRI. (A) White matter hyperintensities. (B) Lacunar infarct. (C) Cavernous malformation.
(D) Malformation of venous development. (E) Arachnoid cyst. (F) Meningioma. (G) Non-specific focus of altered signal. (H) Brain
volume loss. (I) Chiari malformation type I. (J) Otorhinolaryngology process. (K) Ventriculomegaly suspicious of NPH. (L) Brain
stem atrophy.
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Nevertheless, some other papers report much higher
prevalence rates.9 These discrepancies can be mostly
accounted for by the criteria for defining what constitu-
tes an IF, technical features (type and quality of MRI
sequences and the training of the scan reader)13 28–30
and the characteristics of participants included (pres-
ence of comorbidities, screening selection and ethni-
city).28 29 For instance, in a retrospective study that
included 1000 asymptomatic volunteers, only 18% of
them presented with IF.7 In comparison to our study, the
age range of their population (3–83 years old) was wider
including very young participants who are less prone to
the present parenchyma atrophy or vascular pathology.
Overall, we found a positive correlation between the
prevalence of IF and increasing age, while no sex-
specific differences appeared significant. In addition to
participant’s age, the resolution of the MRIs used in pre-
vious studies was generally worse, thus reducing their
capability of detecting microbleeds or small cavernomas.
In general, a higher prevalence of IF is reported
in studies using at least one high-resolution
sequence.8 9 13 30–33 A T2-weighted GRE facilitates the
detection of haemorrhage, cerebral microbleeds and cal-
cifications.34 A T2-weighted sequence is especially sensi-
tive in detecting infratentorial brain pathology;
meanwhile, FLAIR is dedicated to identifying small
vessel disease.34 On the other hand, we did not use
contrast-enhanced MRI. The absence of contrast is
thought to leave some small lesions unnoticed,6 and
underestimate the prevalence of IF.13
Differences in the definition of IF also contribute to
the variation of the reported IF prevalence among previ-
ous studies in the literature. In most of them,8 13 28–30
the classification of IF was based on previous guide-
lines,28 consisting of three categories as a function of
their clinical relevance. In our case, we chose to categor-
ise any structural finding discovered as an IF regardless
of its clinical relevance. In this regard, other studies did
not include WMH as an IF,13 28 29 which were reported
as age-related changes. However, we considered WMH
with a Fazekas score ≥2 as IF, because they have been
regarded as secondary to small vessel pathology by other
authors.25–27 35 WMH have important clinical and risk
factor associations, underlining that they should not be
ignored as inevitable ‘silent’ consequences of the physio-
logical ageing of the brain.36 In our study, 7.8% of the
participants presented with relevant WMH (Fazekas
score ≥2) and their prevalence significantly increased
with advancing age. These results confirm previous find-
ings where a 10-fold increase in the prevalence of WMH
was found in participants older than 55, especially in
those with risk factors for small vessel disease such as
hypertension and diabetes.3 11 13 Nevertheless, the
prevalence of WMH in our study is lower than in other
works evaluating IF in healthy individuals, most likely
because those included older participants.7 9 10 37
Asymptomatic lacunar infarcts are frequently reported
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Our results are in agreement with previous studies report-
ing that lacunes are common IF in the brains of indivi-
duals in their 60s, and their prevalence as well as size
increased with age.9 38 39
As far as brain volume loss is concerned, 7.0% of our
study’s participants presented with brain volume loss
greater than that expected by age and its prevalence sig-
nificantly increased with increasing age. One study
involving older participants (73 years old) revealed a
slightly higher brain volume loss prevalence (18%) than
ours.7 In this regard, it has to be noted that the inclu-
sion criteria for our study were very strict in the defin-
ition of normal cognition. Therefore, participants with
subclinical cognitive impairment may have been
excluded from the study, thus resulting in a lower preva-
lence of cortical atrophies. Generally, brain volume loss
is not considered an IF since it is relatively normal in
the elderly.3 28 30 However, we considered those with
brain volume loss greater than that expected by age as
an IF because their manifestation may reflect the pres-
ence of subclinical pathology. Indeed, it is known that
the rate of progression of global and regional brain
atrophy is associated with future cognitive deterioration
and conversion to dementia.40–42 Unexpectedly, indivi-
duals without a family history of AD showed a greater
prevalence of abnormal brain atrophies for their age.
However, this difference was driven by atrophies in the
frontal lobe, and therefore it cannot be attributable to
early AD pathology. In regions known to be affected by
AD, such as the temporal and parietal cortices, no differ-
ences in atrophy prevalence were found between partici-
pants with and without a familiar history of AD.
With regard to gender-specific distribution of IF, statis-
tically significant differences between genders were
found in the prevalence of brain volume loss that was
more frequent in men, and neoplasias that were more
prevalent in women. Within the latter, and similarly to
previous works,3 7–9 13 28 meningiomas were the most
common neoplastic brain finding (1.7%). The incidence
of meningiomas has been reported to be about three-
fold higher in women, with the greatest difference
observed between the ages of 30 and 59.43 In our study,
the higher prevalence of meningiomas found than in a
previously reported study (0.9% in ref. 13) may be attrib-
uted to the use of MRIs of higher spatial resolution.
Asymptomatic meningiomas require close clinical and
radiological follow-up to rule out quickly enlarging
tumours.43
Our sample was selected through a very accurate screen-
ing process to ensure that participants included were clin-
ically and cognitively normal. Nevertheless, although
Chiari malformations constituted an exclusion criterion,
we found six participants who were unaware of harbouring
them. Another strength of our study, which may lead to a
higher reported prevalence, is that the MRI protocol was
uniform for all participants and high-resolution MRI
sequences were used. In addition, all images were reviewed
by the same neuroradiologist, thus maximising the
homogeneity of the readings and reports. Indeed, the
experience of the reader is another factor that has an
influence on the detection of IF.13 29–34 44–46
The strict recruitment criteria in the ALFA study may
underlie the main limitation of this study in that the
results reported here may not reflect the prevalence of
IF in the general population. A greater percentage of
our volunteers were first-degree descendants of patients
with AD than what would be expected from the general
population. Therefore, our prevalence estimates should
not be regarded from an epidemiological perspective,
but are of interest for design of AD prevention trials.
Another limitation is the operationalisation of family
history status as enrichment criteria for these trials.
Ideally, family history should be supported by clinical
records that might be difficult to access. In our cohort,
53% of the cases with a positive family history were
backed up by confirmed medical records. On top of
this, there is a certain arbitrariness in establishing a
cut-off value in the age of AD onset in the index case to
determine a positive family history status and selecting
different threshold values may impact the observed
prevalence estimates. In the ALFA cohort, this threshold
is fixed at <75 years based on previous literature support-
ing that the age of AD onset in the index case needs to
be limited as dementia occurring at a very old age is less
likely to have a strong genetic component.47 48 This
75-year-old limit has been used by us and other studies
that combine multiple susceptibility loci into a global
genetic risk score to improve the prediction of indivi-
duals at risk of suffering AD.49
There is still an open debate regarding the disclosure
of IF to participants participating in imaging studies,
since there is still a lack of evidence on which to base
practice on the balance of harm versus benefit in telling
research participants about findings.5 The existing litera-
ture has evaluated the will of participants in medical
and non-medical settings to be informed. In this respect,
among study participants surveyed in the USA in 2005,
90% of 105 respondents said that they would to be
informed of any IF, of whom 60% preferred this to be
done by a physician in the research team.50 In any case,
further research to better understand the clinical and
ethical implications of IF and their disclosure is needed
for developing evidence-based policies for their manage-
ment. In our study, volunteers were informed about our
policy to disclose non-clinically relevant findings and
agreed so by signing the study’s informed consent form.
All participants received a radiological report of their
MRI (not just those presenting a finding (it being clinic-
ally relevant or not), but also those presenting no find-
ings at all). A trained physician explained the findings
to participants in order to provide clear information
about their clinical relevance or lack of it. Clinically rele-
vant findings were referred for specialist follow-up.
Non-clinically relevant findings were also reported and
volunteers were facilitated by a helpline should they
have further questions or needed additional
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clarifications. Even though we did not measure the psy-
chological impact of disclosing non-clinically relevant
findings, it is worth mentioning that out of the 65
events, none of them ever made use of this helpline. In
general, we did not perceive any case in which disclosure
caused any inconvenience: participants acknowledged
the information and felt the feedback positively.
Nevertheless, it would be interesting to investigate the
psychological impact of knowing these findings on the
quality of life of these participants.
In conclusion, we describe here that brain MRIs of
healthy middle-aged participants show a relatively high
prevalence of IF (27.0%) even after excluding individuals
with subtle cognitive alterations. As a whole, a positive cor-
relation between the prevalence of IF and increasing age
was found and, within specific IF categories, relevant
WMH, lacunes and brain volume loss prevalence signifi-
cantly increased with age. Jointly, no significant differences
between genders in the general prevalence of IF were
found. However, brain volume loss was more frequent in
men and neoplasias were more prevalent in women.
The main limitation of this study is the particular
recruitment criteria in the ALFA project which argues
against the generalisation of our data in the general
population. In addition, the difficulty in establishing a
cut-off value in the age of AD onset in the index case may
have an impact on whether IF are more prevalent in first-
degree relatives of patients with AD. Nevertheless, it is
worth mentioning that most of our participants are first-
degree descendants of patients with AD, and therefore
the results presented here are of special relevance for
novel imaging studies in the context of AD prevention in
cognitively healthy middle-aged participants.
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